Epic Sciences nets Myriad’s cancer president to serve as its CEO

board room
Epic raised $52 million last fall for its line of blood tests that aim to predict responses to cancer therapies and combinations, and detect early drug resistance. (Jim Frech)

Liquid biopsy developer Epic Sciences has brought on Myriad Genetics’ oncology chief, Lloyd Sanders, to be its new president and CEO.

Sanders takes over for Murali Prahalad—who is stepping down after six years to pursue new opportunities, according to the company—though Prahalad will maintain a seat on Epic’s board of directors.

"Under Murali's leadership, the Epic team has made substantial progress in advancing our proprietary Functional Cell Profiling platform and successfully launching and obtaining Medicare coverage for the world's first predictive test for metastatic prostate cancer," Epic’s chairman, Gregory Lucier, said in a statement.

Sponsored by Biotech Primer

September 2-3, 2020 Live, Online Course: Biopharma Revenue Forecasting that Drives Decision Making and Investments

Become fluent in the core elements of revenue forecasting including epidemiology, competitive assessments, market share assignment and pricing. Let Biotech Primer's dynamic industry experts teach you how to assess the value of new therapies.

At Myriad, Sanders helped oversee the cancer, urology and dermatology commercial units as president of its oncology segment. He was also responsible for the sales, marketing and lab operations of several molecular diagnostic products.

Before that, Sanders was the chief operating officer of Mylan’s Dey Pharma division, overseeing sales, marketing and medical affairs for brands including the EpiPen. He also served as COO of the cancer-focused biotech Genta.

RELATED: Epic Sciences gathers $52M for blood tests that match cancer patients to therapies

Last fall, Epic raised $52 million in a series E round to help advance its line of blood tests, which use computer vision and machine learning to identify circulating tumor cells, while characterizing the body’s immune responses. The platform aims to predict individual patients’ responses to different cancer therapies and combinations, as well as to detect early drug resistance.

With Sanders’ tenure, Epic hopes to make inroads to new markets, both domestically and internationally, including in breast cancer and immuno-oncology.

"By expanding the breadth and depth of Epic's portfolio of reimbursed products, and building our thriving biopharma solutions business that supports our pharmaceutical partners' development of next-generation immunotherapies and targeted cancer agents, we can play an important role in changing cancer from a lethal to a chronic, manageable disease," Sanders said.

Suggested Articles

The deal comes almost two years after Roche dropped the tumor microenvironment modulator after putting it through a clutch of early-phase studies.

The buzzy life sciences company Verily is looking to speed up COVID testing with a new lab based at its native South San Francisco.

Although Genfit canned its NASH program last month, it has been plugging away at a blood-based diagnostic for the liver disease.